Led · Seed · Nov 2025

Founded in 2022 in Munich by Prof. Dr. Benjamin Wolf, Simone Sabbione and Martin Sabbione, Meliodays Medical is building MelioOne, a hormone-free, locally acting therapy that releases micro-doses of analgesics directly in the uterus to alleviate menstrual pain. The approach leverages a proven polymer technology, targeting pain at its source while avoiding systemic adverse effects associated with high-dose oral medications or hormones. Period pain affects about 80 % of menstruating people, with up to 30 % experiencing debilitating symptoms, and the company aims to restore their quality of life. Its platform could also be extended to indications such as endometriosis, and patent protection has already been secured in more than 150 countries. The start-up recently secured an oversubscribed pre-seed round exceeding €800 000, providing the resources to complete preparations for preclinical testing of its intra-uterine application. The infusion of capital underpins continued product development and early regulatory planning. To date, Meliodays Medical’s external funding stands at just over €800 000.

Participated · Seed · Feb 2025

QRaGo is a German healthtech digital platform that streamlines external logistics in the healthcare sector, with a focus on patient and material transport. The platform connects medical facilities, laboratories, transport companies and health insurers and offers real-time tracking, automated scheduling and continuous monitoring. Healthcare providers can order transports within 30 seconds and receive arrival and departure updates, while transport companies benefit from automated requests and optimized route planning that reduce costs. QRaGo recently announced partnerships with Uber (transport) and Debeka (health insurance) to broaden its service offering. The company raised a €2.7M Seed round led by āltitude and MobilityFund, completed by existing investors including Segenia Capital and capacura. With the new capital QRaGo plans to expand its reach in the DACH region and enter Austria and Switzerland by year-end.

Participated · Series A · Jan 2024

Myosotis offers a software-as-a-service solution for direct digital communication between employees, relatives, and third-party service providers in care homes. The app supports photos, videos, voice messages and video calls, consolidating most communication and administrative processes into a single digital application. Led by CEO Jasper Böckel, myo enables homes to inform relatives about hygiene measures, let families participate in residents' lives, and notify doctors, pharmacies or external laundry services. The company works with over 400 customers in DACH and the UK, including DRK, AWO, Johanniter and Agaplesion. Myosotis raised €8M in Series A funding and intends to use the proceeds to grow in the DACH region and the UK, expand marketing capacity, enhance service quality, and develop new modules. The financing will support continued roll-out of their technology to more users and additional solutions for healthcare providers and families.